Hear from multiple myeloma subject matter experts Joseph Michael, MD, Med, FRCPC, FACP, and Saad Usmani, MD, MBA, FACP, FASCO, on early detection and referral to hematology for improved patient outcomes.
Researchers to present on topics ranging from molecular residual disease and immunotherapy to whole-genome sequencing BURLINGTON, N.C. , April 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will present abstracts in the areas of
This molecular tumor board where we present a case of recurrent hepatocellular carcinoma (HCC) with interesting immune phenotypes discovered on a comprehensive genomic and immune profiling test. We reviewed TIGIT as a promising target for cancer immunotherapy and outlined the prognosis and treatment paradigm of HCC along with discussing the different stages and potential barriers of clinical trial enrollment.
Transaction to enhance Labcorp's laboratory services network and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 28, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO
A leading Japanese pharmaceutical company chose to partner with Labcorp to provide central laboratory testing services for a complex regional clinical trial. Their flow cytometry (FCM) panel for immunology was planned for a duration of three to four years. The primary challenges were the short stability period (48 hours) of trial samples and the fact that all the trial locations were not yet determined. Labcorp’s efficient logistics enabled speedy shipping for reliable data. By leveraging its worldwide network of accredited central lab facilities that use standardized assays and procedures, Labcorp gave the client the flexibility to conduct trials wherever needed, while ensuring consistent and reliable data that was also combinable.
BURLINGTON, N.C. , March 27, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2024 before the market opens on Thursday, April 25, 2024 .
For patients with non-small cell lung cancer, tissue samples for testing are usually obtained by small biopsies. The standard of care for all patients with non-small cell lung cancer is to evaluate for >10 biomarkers so oncologists can recommend targeted, personalized therapies.
Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care BURLINGTON, N.C. , March 20, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the
After facing early-onset colon cancer, Bridgette is sharing her story of her first colon cancer symptoms and raising awareness of early colon cancer screening.
